VIDEO: BREAKWATER trial improves colorectal cancer response rate
In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.
The randomized multicenter trial examined the combination of encorafenib (Braftovi, Pfizer) and cetuximab (Erbitux, Imclone) in the front-line setting with chemotherapy for the treatment of BRAF V600E-mutated colorectal cancer. Compared with standard of care, the overall response rate had improved from 40% to about 60%.
“Based on this trial, I would say that all patients with BRAF V600E-mutated colorectal cancer should be treated with FOLFOX plus encorafenib-cetuximab in the front-line setting,” Dasari, an associate professor of medical oncology at The University of Texas MD Anderson Cancer Center, said.
Reference:
- Kopetz S, et al. Abstract 16. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 23-25, 2025; San Francisco.
Collapse
Read more about